Illumina, Inc. vs IQIYI Inc - ADR — how do they compare? Illumina, Inc. trades at $265.99 (market cap $39.95B), while IQIYI Inc - ADR trades at $1.02 (market cap $974.67M). The key difference: Illumina, Inc. is far larger — about 41× IQIYI Inc - ADR's market cap, and Illumina, Inc. is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and IQIYI Inc - ADR for 55 Days on average.
| ILMN | IQ | |
|---|---|---|
Market Cap | $39.95B | $974.67M |
Volume | 3,169,503 | 4,964,108 |
Sector | Health | Media |
52-Week High | $293.69 | $2.35 |
52-Week Low | $91.00 | $0.86 |
Typical Hold Time | 83 Days | 55 Days |
Enterprise Value | $41.31B | $2.47B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
IQ trades at $1.015, up 0.5% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29 billion, and negative profit margins persist. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights iQIYI's focus on AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious due to revenue contraction and recurring losses, though AI initiatives offer growth potential. Key risks include competitive pressures in streaming and reliance on Chinese market dynamics. Institutional ownership trends and earnings performance in upcoming quarters will be critical for stock direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →